drugset / Trial / NCT00697970

Evaluation of Immunogenicity and Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine

NCT00697970

Phase 3 Completed 321 enrolled GlaxoSmithKline
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of the present trial is to evaluate 6 vaccine formulations of recombinant hepatitis B vaccine for their reactogenicity and immunogenicity when administered at 0-2 months with a booster at month 12

Timeline

Start
1993-11
Primary completion
1995-04
Completion
1995-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Engerix-B Vaccine Intramuscular
Subject Hepatitis B vaccine Vaccine Intramuscular